APM
ORIC icon

Avidity Partners Management’s Oric Pharmaceuticals ORIC Stock Holding History

Avidity Partners Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,265,200
Closed -$10.2M – 81
2024
Q4 		$10.2M Sell
1,265,200
-181,919
-13% -$1.67M 1% 39
2024
Q3 		$14.8M Buy
+1,447,119
New +$14.3M 0.76% 49

Other funds holding ORIC

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avidity Partners Management's ORIC Position: Q1 2025 in Review

Avidity Partners Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 1,265,200 shares — an estimated $10.2M sold.

Avidity Partners Management first reported a position in ORIC in Q3 2024 and held it in 2 quarters. The position peaked at $14.8M in Q3 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

  • Avidity Partners Management reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Avidity Partners Management sold 1,265,200 Oric Pharmaceuticals shares in Q1 2025, an estimated $10.2M.
  • Avidity Partners Management first reported a position in Oric Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Avidity Partners Management's Oric Pharmaceuticals position peaked at $14.8M in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.